Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 plus Lenvatinib in Advanced HCC
NCT04542837Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2020
- Primary completion
- Feb 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erfonrilimab in hepatocellular carcinoma (HCC), sponsored by Peking University Cancer Hospital & Institute. Started Sep 2020; status: completed.
02
Drugs
erfonrilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04542837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542837.